APRE swing ideaStrong support here and daily CBD formed, potential on weekly CBD RSI and MACD. Potential 4h triple CBD and 1h CBD forming. Seems strong for a push up, could push more above 3.2.
−4.00USD
−14.29 MUSD
583.23 KUSD
4.79 M
About Aprea Therapeutics, Inc.
Sector
CEO
Oren Gilad
Headquarters
Doylestown
Website
Employees (FY)
7
Founded
2002
FIGI
BBG00Q6Q3K37
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
$APRE looking perky $APRE big catalysts within the next 2 weeks. Moves fast on news and major gap to fill.
$APRE next small cap pop!!!! From a technical standpoint we are looking pretty strong as we closed about the 9-day AND the 26-day moving average with high buying pressure whicks which is interesting
Now from a company perspective standpoint we are most likely to first get approval on, this would be like the most expens
MARKET ALPHA OPTIONS WATCHLIST - APRENASDAQ:APRE
Very unusual options activity came in on this one at 4.79 with the assumption the stock would continue higher by August 8th.
Currently the option play is down but that doesn't mean we haven't found support here and may bounce higher catching some off guard. If not the support level is
APREAprea Therapeutics Inc (NASDAQ:APRE) Potential breakout play. Watch the stock closely tomorrow and once it breaks $5.75, get ready to jump in and buy the stock for another swing trade. Stop 5.1
deep cupgoal is to accumulate 800 to 1.5K shares in this thing until we see some major gap fills. Currently sitting on 150 shares, watching it daily. The Street just left it for dead, liking this $5 handle for accum, no stops, buy weakness, just let the pro shorts in this cover and let the chase begin on th
APREOnly way I would want to play this stock is if it broke over the $8.4 resistance area and proved that it could have a gap fill potential (likely would not actually fill this gap but should be able to run a bit more). What I’m not loving about this ticker is the news was ultra fluffy AND there’s a lo
6/6 wins with a few more called out for good luck +$2233.00Hi Guys,
Took a lot of trades today. Whohoo!!!
Thanks,
Enda
APRE longnot much to describe here.
I will just give it a try with a tight stop-loss.
expecting it to fill the gap.
the drop back in dec happened because one of its clinical trials did not succeed.
but they still work on others.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of APRE is 5.62 USD — it has increased by 9.69% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aprea Therapeutics, Inc. stocks are traded under the ticker APRE.
Aprea Therapeutics, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
APRE stock is 9.65% volatile and has beta coefficient of 1.73. Check out the list of the most volatile stocks — is Aprea Therapeutics, Inc. there?
APRE earnings for the last quarter are −0.86 USD per share, whereas the estimation was −1.13 USD resulting in a 23.67% surprise. The estimated earnings for the next quarter are −0.77 USD per share. See more details about Aprea Therapeutics, Inc. earnings.
Aprea Therapeutics, Inc. revenue for the last quarter amounts to 319.47 K USD despite the estimated figure of 125.00 K USD. In the next quarter revenue is expected to reach 165.00 K USD.
Yes, you can track Aprea Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
APRE stock has fallen by 1.98% compared to the previous week, the month change is a 8.38% fall, over the last year Aprea Therapeutics, Inc. has showed a 45.91% increase.
APRE net income for the last quarter is −3.44 M USD, while the quarter before that showed −3.20 M USD of net income which accounts for −7.45% change. Track more Aprea Therapeutics, Inc. financial stats to get the full picture.
Today Aprea Therapeutics, Inc. has the market capitalization of 27.80 M, it has increased by 0.49% over the last week.
No, APRE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, APRE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aprea Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 7.00 employees. See our rating of the largest employees — is Aprea Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aprea Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aprea Therapeutics, Inc. stock shows the sell signal. See more of Aprea Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Aprea Therapeutics, Inc. future price: according to them, APRE price has a max estimate of 20.00 USD and a min estimate of 11.00 USD. Read a more detailed Aprea Therapeutics, Inc. forecast: see what analysts think of Aprea Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aprea Therapeutics, Inc. EBITDA is −15.47 M USD, and current EBITDA margin is −2.65 K%. See more stats in Aprea Therapeutics, Inc. financial statements.